Aspartate 0 9 0 9 B-clinical_variable
aminotransferase 10 26 10 26 I-clinical_variable
( 27 28 27 28 I-clinical_variable
AST 28 31 28 31 I-clinical_variable
) 31 32 31 32 I-clinical_variable
or 33 35 33 35 O
alanine 36 43 36 43 B-clinical_variable
aminotransferase 44 60 44 60 I-clinical_variable
( 61 62 61 62 I-clinical_variable
ALT 62 65 62 65 I-clinical_variable
) 65 66 65 66 I-clinical_variable
< 67 68 67 68 O
3 69 70 69 70 B-upper_bound
times 71 76 71 76 I-upper_bound
ULN 77 80 77 80 I-upper_bound
or 81 83 81 83 O
< 84 85 84 85 O
5 86 87 86 87 B-upper_bound
times 88 93 88 93 I-upper_bound
ULN 94 97 94 97 I-upper_bound
if 98 100 98 100 O
patient 101 108 101 108 O
has 109 112 109 112 O
documented 113 123 113 123 O
liver 124 129 124 129 B-cancer
metastases 130 140 130 140 I-cancer

Candidate 0 9 141 150 O
for 10 13 151 154 O
fulvestrant 14 25 155 166 B-treatment
therapy 26 33 167 174 I-treatment

Creatinine 0 10 175 185 B-clinical_variable
< 11 12 186 187 O
1.5 13 16 188 191 B-upper_bound
times 17 22 192 197 I-upper_bound
ULN 23 26 198 201 I-upper_bound

ECOG 0 4 202 206 B-clinical_variable
PS 5 7 207 209 I-clinical_variable
0 8 9 210 211 B-lower_bound
- 9 10 211 212 O
2 10 11 212 213 B-upper_bound

ER+ 0 3 214 217 B-cancer
Her2- 4 9 218 223 I-cancer
breast 10 16 224 230 I-cancer
cancer 17 23 231 237 I-cancer

Female 0 6 238 244 B-gender

History 0 7 245 252 O
of 8 10 253 255 O
seizures 11 19 256 264 B-chronic_disease

INR 0 3 265 268 B-clinical_variable
< 4 5 269 270 O
1.5 6 9 271 274 B-upper_bound
times 10 15 275 280 I-upper_bound
ULN 16 19 281 284 I-upper_bound

Metastatic 0 10 285 295 B-cancer

Prior 0 5 296 301 B-treatment
treatment 6 15 302 311 I-treatment
with 16 20 312 316 I-treatment
an 21 23 317 319 I-treatment
anti 24 28 320 324 I-treatment
- 28 29 324 325 I-treatment
androgen 29 37 325 333 I-treatment
( 38 39 334 335 O
abiraterone 39 50 335 346 B-treatment
, 50 51 346 347 O
ARN-509 52 59 348 355 B-treatment
, 59 60 355 356 O
bicalutamide 61 73 357 369 B-treatment
, 73 74 369 370 O
enzalutamide 75 87 371 383 B-treatment
, 87 88 383 384 O
ODM-201 89 96 385 392 B-treatment
, 96 97 392 393 O
TAK-448 98 105 394 401 B-treatment
, 105 106 401 402 O
TAK-683 107 114 403 410 B-treatment
, 114 115 410 411 O
TAK-700 116 123 412 419 B-treatment
, 123 124 419 420 O
VT-464 125 131 421 427 B-treatment
) 131 132 427 428 O

Subjects 0 8 429 437 O
should 9 15 438 444 O
use 16 19 445 448 B-contraception_consent
2 20 21 449 450 I-contraception_consent
acceptable 22 32 451 461 I-contraception_consent
methods 33 40 462 469 I-contraception_consent
of 41 43 470 472 I-contraception_consent
birth 44 49 473 478 I-contraception_consent
control 50 57 479 486 I-contraception_consent
( 58 59 487 488 O
one 59 62 488 491 O
of 63 65 492 494 O
which 66 71 495 500 O
must 72 76 501 505 O
include 77 84 506 513 O
a 85 86 514 515 O
condom 87 93 516 522 B-contraception_consent
as 94 96 523 525 O
a 97 98 526 527 O
barrier 99 106 528 535 O
method 107 113 536 542 O
of 114 116 543 545 O
contraception 117 130 546 559 O
) 130 131 559 560 O
starting 132 140 561 569 O
at 141 143 570 572 O
the 144 147 573 576 O
time 148 152 577 581 O
of 153 155 582 584 O
screening 156 165 585 594 O
for 166 169 595 598 O
an 170 172 599 601 O
enzalutamide 173 185 602 614 B-treatment
study 186 191 615 620 O
and 192 195 621 624 O
continuing 196 206 625 635 O
throughout 207 217 636 646 O
the 218 221 647 650 O
course 222 228 651 657 O
of 229 231 658 660 O
treatment 232 241 661 670 B-treatment
and 242 245 671 674 O
for 246 249 675 678 O
at 250 252 679 681 O
least 253 258 682 687 O
three 259 264 688 693 B-lower_bound
months 265 271 694 700 I-lower_bound
after 272 277 701 706 O
enzalutamide 278 290 707 719 O
is 291 293 720 722 O
discontinued 294 306 723 735 O

Total 0 5 736 741 B-clinical_variable
bilirubin 6 15 742 751 I-clinical_variable
< 16 17 752 753 O
1.5 18 21 754 757 B-upper_bound
times 22 27 758 763 I-upper_bound
upper 28 33 764 769 I-upper_bound
limit 34 39 770 775 I-upper_bound
of 40 42 776 778 I-upper_bound
normal 43 49 779 785 I-upper_bound
( 50 51 786 787 I-upper_bound
ULN 51 54 787 790 I-upper_bound
) 54 55 790 791 I-upper_bound
at 56 58 792 794 O
the 59 62 795 798 O
screening 63 72 799 808 O
visit 73 78 809 814 O
unless 79 85 815 821 O
an 86 88 822 824 O
alternate 89 98 825 834 O
nonmalignant 99 111 835 847 O
etiology 112 120 848 856 O
exists 121 127 857 863 O
( 128 129 864 865 O
eg 129 131 865 867 O
, 131 132 867 868 O
Gilbert 133 140 869 876 B-chronic_disease
's 140 142 876 878 I-chronic_disease
disease 143 150 879 886 I-chronic_disease
) 150 151 886 887 O

Vaginal 0 7 888 895 B-treatment
estrogens 8 17 896 905 I-treatment
are 18 21 906 909 O
allowed 22 29 910 917 O
if 30 32 918 920 O
necessary 33 42 921 930 O
for 43 46 931 934 O
patient 47 54 935 942 O
comfort 55 62 943 950 O

at 0 2 951 953 O
least 3 8 954 959 O
18 9 11 960 962 B-lower_bound
years 12 17 963 968 I-lower_bound
of 18 20 969 971 O
age 21 24 972 975 B-age

two 0 3 976 979 O
biopsies 4 12 980 988 B-treatment
- 13 14 989 990 O
pretreatment 15 27 991 1003 B-treatment
as 28 30 1004 1006 O
regards 31 38 1007 1014 O
enzalutamide 39 51 1015 1027 B-treatment
, 51 52 1027 1028 O
and 53 56 1029 1032 O
during 57 63 1033 1039 O
treatment 64 73 1040 1049 O
at 74 76 1050 1052 O
4 77 78 1053 1054 B-upper_bound
weeks 79 84 1055 1060 I-upper_bound

